Sphera Funds Management LTD. lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 474,103 shares of the biopharmaceutical company's stock after buying an additional 55,000 shares during the quarter. Celldex Therapeutics comprises about 2.2% of Sphera Funds Management LTD.'s holdings, making the stock its 11th biggest holding. Sphera Funds Management LTD. owned 0.71% of Celldex Therapeutics worth $11,981,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also modified their holdings of the company. Values First Advisors Inc. lifted its position in shares of Celldex Therapeutics by 20.0% during the 4th quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock worth $733,000 after buying an additional 4,837 shares during the last quarter. Barclays PLC lifted its position in shares of Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after buying an additional 76,207 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Celldex Therapeutics by 24.4% during the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 4,967 shares during the last quarter. Invesco Ltd. lifted its position in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after buying an additional 871 shares during the last quarter. Finally, Sovran Advisors LLC purchased a new stake in shares of Celldex Therapeutics during the 4th quarter worth approximately $2,867,000.
Celldex Therapeutics Trading Up 2.2%
Shares of NASDAQ:CLDX traded up $0.46 on Monday, reaching $20.91. 614,375 shares of the company were exchanged, compared to its average volume of 892,075. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -8.14 and a beta of 1.39. The company has a 50-day moving average of $18.91 and a 200-day moving average of $22.55.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. As a group, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts recently commented on the stock. Morgan Stanley reduced their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. The Goldman Sachs Group cut their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. UBS Group cut their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $53.90.
Check Out Our Latest Report on CLDX
Celldex Therapeutics Profile
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Articles
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
